Trial description:
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation.
Contact name:
Dr George Follows
Trial start date:
Tuesday, October 13, 2020
Trial end date:
Sunday, February 28, 2021
Trial tumour type:
Haematological
Show on Radiotherapy:
No
